+ Site Statistics
References:
54,258,434
Abstracts:
29,560,870
PMIDs:
28,072,757
+ Search Articles
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ PDF Full Text
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Translate
+ Recently Requested

OptiPen Pro--more safety for Insulin injections



OptiPen Pro--more safety for Insulin injections



Krankenpflege Journal 37(10): 394-394




(PDF emailed within 1 workday: $29.90)

Accession: 046870602

Download citation: RISBibTeXText

PMID: 10693457


Related references

A comparison of efficacy and safety in the treatment of hyperglycemia with continuous subcutaneous insulin with insulin pump or multiple insulin injections daily in critical elderly patients. Zhongguo Wei Zhong Bing Ji Jiu Yi Xue 20(9): 546-549, 2008

Injection aids for intermediate-term acting insulin. Experiences with the OptiPen. Fortschritte der Medizin 107(15): 348-350, 1989

Feasibility and acceptability of insulin therapy using a pen suitable for injecting regular or intermediate insulin. Results of the French multicenter study conducted by the Optipen-France Study Group. Diabete & Metabolisme 16(6): 492-497, 1990

28-week, randomized, multicenter, open-label, parallel-group phase III trial to investigate the efficacy and safety of biphasic insulin aspart 70 thrice-daily injections vs twice-daily injections of biphasic insulin aspart 30 in patients with type 2 diabetes. Journal of Diabetes Investigation 1(3): 103-110, 2010

Feasibility and safety of multiple daily insulin injections in general medicine wards. European Journal of Internal Medicine 20(4): 435-439, 2009

Comparative study of effectiveness of multiple-daily injections of insulin versus twice-daily injections of biphasic insulin in patients with type 2 diabetes. Endocrine Journal 56(2): 193-200, 2008

A quality-of-life assessment of intensive insulin therapy using insulin lispro switched from short-acting insulin and measured by an ITR-QOL questionnaire: a prospective comparison of multiple daily insulin injections and continuous subcutaneous insulin infusion. Diabetes Research and Clinical Practice 64(1): 19-25, 2004

Intermediary metabolism, insulin sensitivity and insulin receptor status under comparable long-term therapy with insulin injections and continuous subcutaneous insulin infusion. Acta Endocrinologica 117(4): 417-427, 1988

Comparison of continuous subcutaneous insulin infusion and insulin glargine-based multiple daily insulin aspart injections with preferential adjustment of basal insulin in patients with type 2 diabetes. Experimental and Therapeutic Medicine 8(4): 1191-1196, 2014

Six-month multicentric, open-label, randomized trial of twice-daily injections of biphasic insulin aspart 30 versus multiple daily injections of insulin aspart in Japanese type 2 diabetic patients (JDDM 11). Diabetes Research and Clinical Practice 79(1): 171-176, 2007

Safety of repeat intravitreal injections of bevacizumab versus ranibizumab: our experience after 2,000 injections. Retina 29(3): 313-318, 2009

Efficacy and safety of corticosteroid injections and other injections for management of tendinopathy: a systematic review of randomised controlled trials. Lancet 376(9754): 1751-1767, 2010

Influence of BMI, age and duration of diabetes mellitus on glycaemic control with twice-daily injections of biphasic insulin aspart 30 versus multiple daily injections of insulin Aspart retrospective reanalysis of a 6-month, randomized, open-label, multicentre trial in Japan. Clinical Drug Investigation: 1, 35-40, 2010

Influence of BMI, Age and duration of diabetes mellitus on glycaemic control with twice-daily injections of biphasic insulin aspart 30 versus multiple daily injections of insulin aspart (JDDM 18): retrospective reanalysis of a 6-month, randomized, open-label, multicentre trial in Japan. Clinical Drug Investigation 30(1): 35-40, 2010